ft538
Recombinant proteinexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2020 (NCT04614636)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Art · Phase 1
- CD4-Positive T-Lymphocytes · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- HIV Infections · Phase 1
- Infections · Phase 1
- Interleukins · Phase 1
- Leukemia, Monocytic, Acute · Phase 1
- Leukemia, Myeloid · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
Mechanism of action
FCGR3A binding agent
Chemistry & pharmacology
- Payload
- IL15
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05700630 | Phase 1 | Jul 15, 2024 | University of Minnesota |
| NCT05708924 | Phase 1 | Apr 28, 2023 | University of Minnesota |
| NCT04714372 | Phase 1 | Nov 3, 2021 | University of Minnesota |
| NCT05069935 | Phase 1 | Oct 15, 2021 | Fate Therapeutics |
| NCT04614636 | Phase 1 | Nov 30, 2020 | Fate Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Minnesota | Academic/Hospital | 3 | 3 | 1 | 2021 |
| Fate Therapeutics | For profit | 2 | 2 | 1 | 2020 |
2 organizations
Page 1 / 1